Frontiers in Psychiatry
September 19, 2023
Hillary Jackson, Sara So, Abigail Yaffe et al.
87 citations
A large prospective survey of adults planning to take psilocybin outside clinical settings found that, on average, participants reported lasting reductions in anxiety, depression, and alcohol misuse, along with improvements in cognitive flexibility, emotion regulation, spiritual wellbeing, and extraversion, and decreases in neuroticism and burnout after use. However, a minority reported persisting negative effects: 11% at 2–4 weeks and 7% at 2–3 months after use, including mood fluctuations and depressive symptoms. The study included 2,833 respondents at baseline, 1,182 at 2–4 weeks, and 657 at 2–3 months post-use. Participants were primarily college-educated White men in the United States, mean age 40, who used dried psilocybin mushrooms (mean dose 3.1 grams) for self-exploration.
International Journal of Wellbeing
February 28, 2023
Trey Brasher, David Rosen, Marcello Spinella
9 citations
People who have used classical psychedelics report greater psychological strengths and well-being, and lower distress, compared to those who have not, even after accounting for demographics, beliefs about psychedelics, and use of other drugs. These benefits contrast with cannabis and alcohol users, who show more maladaptive profiles. The relationship between psychedelic use and psychological strengths is fully explained by self-transcendence. Users with a 'growth' motivation show the most adaptive psychological profile. Psychedelic users also report more lifetime meditation experience, but meditation does not account for the differences in strengths, well-being, or distress. Causality cannot be inferred.
Journal of psychoactive drugs
March 15, 2025
Trey Brasher, David Rosen, Marcello Spinella
1 citation
People who use psychedelics report lower symptoms of behavioral addictions such as problem gambling, sexual addiction, compulsive buying, and eating disorders, along with greater well-being, even after accounting for demographics and other drug use. In a community sample of 1107 adults, psychedelic use uniquely predicted lower behavioral addiction scores, while major stimulant, alcohol, and nicotine vaping use predicted higher scores. Behavioral addiction symptoms were inversely correlated with well-being measures. These findings suggest psychedelics may help treat behavioral addictions, warranting a controlled pilot study or clinical trial.